Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

High Mobility Group Box 1 in Pig Amniotic Membrane Experimentally Infected with E. coli O55.

Tytuł:
High Mobility Group Box 1 in Pig Amniotic Membrane Experimentally Infected with E. coli O55.
Autorzy:
Splichal I; Laboratory of Gnotobiology, Institute of Microbiology of the Czech Academy of Sciences, 54922 Novy Hradek, Czech Republic.
Splichalova A; Laboratory of Gnotobiology, Institute of Microbiology of the Czech Academy of Sciences, 54922 Novy Hradek, Czech Republic.
Źródło:
Biomolecules [Biomolecules] 2021 Aug 03; Vol. 11 (8). Date of Electronic Publication: 2021 Aug 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, 2011-
MeSH Terms:
Escherichia coli/*pathogenicity
Escherichia coli Infections/*veterinary
HMGB1 Protein/*genetics
Pregnancy Complications, Infectious/*veterinary
RNA, Messenger/*genetics
Receptor for Advanced Glycation End Products/*genetics
Toll-Like Receptor 4/*genetics
Amnion/immunology ; Amnion/microbiology ; Amnion/pathology ; Amniotic Fluid/immunology ; Amniotic Fluid/microbiology ; Animals ; Disease Models, Animal ; Escherichia coli/growth & development ; Escherichia coli Infections/genetics ; Escherichia coli Infections/immunology ; Escherichia coli Infections/microbiology ; Female ; Gene Expression Regulation ; HMGB1 Protein/immunology ; Host-Pathogen Interactions/genetics ; Host-Pathogen Interactions/immunology ; Humans ; Pregnancy ; Pregnancy Complications, Infectious/genetics ; Pregnancy Complications, Infectious/immunology ; Pregnancy Complications, Infectious/microbiology ; Premature Birth/prevention & control ; RNA, Messenger/immunology ; Receptor for Advanced Glycation End Products/immunology ; Signal Transduction ; Swine ; Toll-Like Receptor 4/immunology
References:
Annu Rev Med. 2018 Jan 29;69:349-364. (PMID: 29106804)
J Immunol. 2001 Feb 1;166(3):1938-44. (PMID: 11160242)
Intensive Care Med. 2008 Jun;34(6):1046-53. (PMID: 18297269)
Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1768-73. (PMID: 11734424)
Cell. 2006 Feb 24;124(4):783-801. (PMID: 16497588)
Mol Aspects Med. 2014 Dec;40:1-116. (PMID: 25010388)
Clin Transl Immunology. 2020 Apr 14;9(4):e1121. (PMID: 32313651)
Front Immunol. 2020 Mar 20;11:484. (PMID: 32265930)
Curr Pharm Des. 2018;24(9):960-973. (PMID: 29384054)
Front Immunol. 2020 Aug 25;11:1918. (PMID: 32983116)
J Leukoc Biol. 2019 Jul;106(1):161-169. (PMID: 30946496)
mSphere. 2020 May 6;5(3):. (PMID: 32376701)
Theriogenology. 2013 Oct 15;80(7):693-705. (PMID: 23849255)
Am J Reprod Immunol. 2015 Jun;73(6):507-21. (PMID: 25605324)
Nat Rev Immunol. 2020 Feb;20(2):95-112. (PMID: 31558839)
Mol Immunol. 2013 Dec;56(4):739-44. (PMID: 23954397)
Aust N Z J Obstet Gynaecol. 2019 Dec;59(6):781-790. (PMID: 31617207)
Am J Physiol Lung Cell Mol Physiol. 2010 Dec;299(6):L852-60. (PMID: 20935228)
Cytokine. 2016 May;81:82-7. (PMID: 26954343)
Science. 1999 Jul 9;285(5425):248-51. (PMID: 10398600)
Placenta. 2007 May-Jun;28(5-6):477-81. (PMID: 17055575)
Science. 2014 Aug 15;345(6198):760-5. (PMID: 25124429)
Paediatr Respir Rev. 2019 Aug;31:82-88. (PMID: 31103368)
Int J Mol Sci. 2019 Dec 13;20(24):. (PMID: 31847111)
Annu Rev Immunol. 1994;12:991-1045. (PMID: 8011301)
Cell. 2010 Mar 19;140(6):805-20. (PMID: 20303872)
Am J Obstet Gynecol. 2007 Feb;196(2):181.e1-13. (PMID: 17306673)
Am J Obstet Gynecol. 2015 Oct;213(4 Suppl):S29-52. (PMID: 26428501)
Horm Cancer. 2018 Oct;9(5):295-325. (PMID: 29987748)
Infect Immun. 2003 Oct;71(10):6058-62. (PMID: 14500530)
J Immunol. 2011 Mar 1;186(5):3248-57. (PMID: 21270403)
Sci Transl Med. 2013 May 15;5(185):185ra64. (PMID: 23677593)
J Physiol. 2010 Dec 15;588(Pt 24):4859-69. (PMID: 21041526)
Reproduction. 2016 Dec;152(6):R277-R292. (PMID: 27679863)
Front Immunol. 2018 Feb 14;9:220. (PMID: 29491864)
Eur J Pharmacol. 2019 Sep 5;858:172487. (PMID: 31229535)
Am J Pathol. 2018 Nov;188(11):2629-2643. (PMID: 30314768)
Vet Immunol Immunopathol. 2002 Aug;87(1-2):11-8. (PMID: 12052338)
Am J Obstet Gynecol. 2015 Dec;213(6):836.e1-836.e18. (PMID: 26232508)
Cytokine Growth Factor Rev. 2019 Aug;48:24-31. (PMID: 31296363)
Reproduction. 2016 Nov;152(5):R179-89. (PMID: 27486265)
J Immunol. 2006 Dec 1;177(11):7889-97. (PMID: 17114460)
Nat Rev Immunol. 2016 Jan;16(1):35-50. (PMID: 26711677)
Cold Spring Harb Symp Quant Biol. 1989;54 Pt 1:1-13. (PMID: 2700931)
Am J Reprod Immunol. 2016 Jan;75(1):3-7. (PMID: 26781934)
Nat Commun. 2018 Jun 20;9(1):2414. (PMID: 29925843)
Front Physiol. 2020 Jun 25;11:581. (PMID: 32670078)
Immunity. 2011 May 27;34(5):637-50. (PMID: 21616434)
Int Immunopharmacol. 2018 Jun;59:391-412. (PMID: 29730580)
J Matern Fetal Neonatal Med. 2012 Jul;25(7):1148-55. (PMID: 21942553)
Am J Physiol Regul Integr Comp Physiol. 2009 Sep;297(3):R525-45. (PMID: 19515978)
Toxins (Basel). 2020 Aug 23;12(9):. (PMID: 32842482)
Cytokine. 2012 Dec;60(3):597-600. (PMID: 22902066)
Vaccine. 2003 Jul 28;21(24):3365-9. (PMID: 12850341)
EMBO Rep. 2002 Oct;3(10):995-1001. (PMID: 12231511)
Infect Immun. 2000 Sep;68(9):5254-60. (PMID: 10948152)
Dev Comp Immunol. 2009 Mar;33(3):384-93. (PMID: 18761034)
Endocrinology. 2015 Oct;156(10):3828-41. (PMID: 26151355)
Nat Rev Immunol. 2010 Dec;10(12):826-37. (PMID: 21088683)
Reprod Sci. 2016 Jan;23(1):69-80. (PMID: 26156854)
Trends Endocrinol Metab. 2004 Dec;15(10):479-87. (PMID: 15541647)
Carbohydr Res. 2003 Nov 14;338(23):2431-47. (PMID: 14670707)
Semin Immunol. 2018 Aug;38:40-48. (PMID: 29530410)
J Biol Chem. 2007 Jun 1;282(22):16336-44. (PMID: 17403684)
Am J Obstet Gynecol. 2007 Nov;197(5):518.e1-8. (PMID: 17980193)
Am J Reprod Immunol. 2005 May;53(5):255-60. (PMID: 15833104)
Am J Reprod Immunol. 2014 Nov;72(5):458-74. (PMID: 25078709)
Immunol Rev. 2017 Nov;280(1):74-82. (PMID: 29027228)
Am J Obstet Gynecol. 2019 Aug;221(2):83-85. (PMID: 31358235)
J Clin Immunol. 2011 Jun;31(3):488-97. (PMID: 21225449)
Am J Obstet Gynecol. 2012 Dec;207(6):475.e1-475.e14. (PMID: 23111115)
Trends Immunol. 2005 Jul;26(7):381-7. (PMID: 15978523)
Am J Obstet Gynecol. 1991 May;164(5 Pt 1):1317-26. (PMID: 2035575)
Cell Mol Immunol. 2017 Jan;14(1):43-64. (PMID: 27569562)
J Matern Fetal Neonatal Med. 2012 Jun;25(6):558-67. (PMID: 22578261)
Nat Methods. 2012 Jul;9(7):671-5. (PMID: 22930834)
Folia Microbiol (Praha). 2004;49(6):751-6. (PMID: 15881414)
J Immunol. 2009 Jun 1;182(11):7244-53. (PMID: 19454721)
Lancet. 2008 Jan 5;371(9606):75-84. (PMID: 18177778)
Physiol Res. 2002;51(5):523-8. (PMID: 12470205)
J Perinat Med. 2008;36(5):388-98. (PMID: 18593373)
EMBO J. 2003 Oct 15;22(20):5551-60. (PMID: 14532127)
J Matern Fetal Neonatal Med. 2011 Dec;24(12):1444-55. (PMID: 21958433)
Contributed Indexing:
Keywords: Toll-like receptor; amniotic fluid; amniotic membrane; cytokines; high mobility group box 1; intra-amniotic infection; pig; preterm birth; receptor for advanced glycation endproducts
Substance Nomenclature:
0 (HMGB1 Protein)
0 (RNA, Messenger)
0 (Receptor for Advanced Glycation End Products)
0 (Toll-Like Receptor 4)
Entry Date(s):
Date Created: 20210827 Date Completed: 20210927 Latest Revision: 20210927
Update Code:
20240104
PubMed Central ID:
PMC8393629
DOI:
10.3390/biom11081146
PMID:
34439812
Czasopismo naukowe
Intra-amniotic infections (IAI) are one of the reasons for preterm birth. High mobility group box 1 (HMGB1) is a nuclear protein with various physiological functions, including tissue healing. Its excessive extracellular release potentiates inflammatory reaction and can revert its action from beneficial to detrimental. We infected the amniotic fluid of a pig on the 80th day of gestation with 1 × 10 4 colony forming units (CFUs) of E. coli O55 for 10 h, and evaluated the appearance of HMGB1, receptor for glycation endproducts (RAGE), and Toll-like receptor (TLR) 4 in the amniotic membrane and fluid. Sham-infected amniotic fluid served as a control. The expression and release of HMGB1 were evaluated by Real-Time PCR, immunofluorescence, immunohistochemistry, and ELISA. The infection downregulated HMGB1 mRNA expression in the amniotic membrane, changed the distribution of HMGB1 protein in the amniotic membrane, and increased its level in amniotic fluid. All RAGE mRNA, protein expression in the amniotic membrane, and soluble RAGE level in the amniotic fluid were downregulated. TLR4 mRNA and protein expression and soluble TLR4 were all upregulated. HMGB1 is a potential target for therapy to suppress the exaggerated inflammatory response. This controlled expression and release can, in some cases, prevent the preterm birth of vulnerable infants. Studies on suitable animal models can contribute to the development of appropriate therapy.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies